Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

119.48 +0.98 (+0.83%)
Streaming Delayed Price Updated: 12:39 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
From Natera, Inc.
Via Business Wire
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
From Natera, Inc.
Via Business Wire
Analyst Expectations for Natera's Future
Via Benzinga
The Latest Analyst Ratings for Natera
Via Benzinga
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
From Natera, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
From Natera, Inc.
Via Business Wire
Natera's Earnings Outlook
Via Benzinga
Why Natera Stock Is Leading Its Industry Group With A 17% Jump Today
Natera snagged a key win that could help extend its patient pool. 
Via Investor's Business Daily
Natera Reports First Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Natera Announces First Quarter 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
From Natera, Inc.
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Catalent Stock Showing Improved Relative Strength Rating
On Friday, Catalent stock earned a positive adjustment to its Relative Strength (RS) Rating, from 63 to 74. 
Via Investor's Business Daily
Natera Announces Commercial Payor Coverage for Signatera™
From Natera, Inc.
Via Business Wire
Natera Reports Fourth Quarter and Full Year 2022 Financial Results
From Natera, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors
From Natera, Inc.
Via Business Wire
Natera Announces Fourth Quarter and Fiscal 2022 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers TravelCenters of America Inc. (NASDAQ: TA) shares jumped 70.5% to $84.32 after BP announced it will acquire the company for $86 per share in cash. 
Via Benzinga
KBR, Twilio, Roku And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 250 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast Cancer
From Natera, Inc.
Via Business Wire
New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
From Natera, Inc.
Via Business Wire
New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
From Natera, Inc.
Via Business Wire
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.